However, a study by Xiao et al. in 2021 [52] keeps LEF1 as a potential therapeutic target for colonic adenocarcinoma, suggesting that it enhances the motility of cancer cells by reshaping the lamellipodia/filopodia and the polymerization of F-actin/β-tubulin. This evidence concerns the gene LEF1 and cancer.